ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis

V. N. Nguyen1, R. Abagyan2, S. Tsunoda2

1Pharmacy, UC San Diego Health, San Diego, CA, 2Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA

Meeting: 2019 American Transplant Congress

Abstract number: D208

Keywords: Adverse effects, Arteriosclerosis, FK506, Sirolimus (SLR)

Session Information

Session Name: Poster Session D: Non-Organ Specific: Pharmacogenomics / Pharmacokinetics

Session Type: Poster Session

Date: Tuesday, June 4, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.

*Methods: Our study utilized the FDA Adverse Event Reporting System (FAERS) database from 2004 through the 2nd quarter of 2018 to perform a retrospective data analysis. We included patients on immunosuppression for kidney, liver, heart, and lung transplantations. In order to isolate AEs due to specific agents, we analyzed reports due to the individual agents tacrolimus, sirolimus, or everolimus, and compared odds ratios of the mTOR inhibitors to tacrolimus. Duplicate adverse events (often a synonym) in the same report, or reported AEs deemed to be unrelated to medication therapy were excluded. AEs were then grouped into 17 main system-based groups using the MedDRA terminologies.

*Results: The mTOR arm had 1282 reports with 4176 AEs while the tacrolimus arm had a total of 7587 reports with 20940 individual AEs. mTOR inhibitors had significantly higher incidences of cardiovascular (OR 1.95, 95% CI 1.70, 2.23), dermatologic (OR 1.34, 95% CI 1.04, 1.73), endocrine (OR 1.52, 95% CI 1.26, 1.82), gastrointestinal (OR 1.15, 95% CI 1.01, 1.30), infectious disease (OR 1.35, 95% 1.20, 1.52), musculoskeletal (OR 1.39, 95% CI 1.13, 1.70), pulmonary (OR 3.46, 95% 2.97, 4.03), renal (OR 1.27, 95% CI 1.10, 1.46), and vascular AEs (OR 3.10, 95% CI 2.14, 4.49). In contrast, mTOR inhibitors had significantly lower reports for neurologic (OR 0.66, 95% CI 0.55, 0.78), psychiatric (OR 0.69, 95% CI 0.48, 0.99), and reproductive (OR 0.66, 95% CI 0.46, 0.95). No differences were found for hematologic, immunologic, malignancies, ophthalmic, and otic. Higher cardiovascular events with mTOR inhibitors was driven mostly by arteriosclerosis, edema, heart failure, and pericardial events. Little is known about the cardiovascular profile of mTOR inhibitors besides edema (everolimus 18-45%, sirolimus 18-20%) and hypertension (everolimus 17-30%, sirolimus 45-49%). The higher incidence rate of arteriosclerosis in the mTOR group has not been reported in the literature and may be explained by dyslipidemia, which is a known complication of mTOR inhibitor therapy.

*Conclusions: We analyzed the adverse event profile of mTOR inhibitors and tacrolimus utilizing a large-scale population database covering 14 years. mTOR inhibitors may be associated with a higher cardiovascular risk. Further analysis is required to determine the potential mechanism of this effect.

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Nguyen VN, Abagyan R, Tsunoda S. mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/mtor-inhibitors-associated-with-higher-cardiovascular-adverse-events-a-large-population-database-analysis/. Accessed May 31, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences